Old Web
English
Sign In
Acemap
>
authorDetail
>
Amy Bullock
Amy Bullock
Sage Group
Medicine
Tolerability
Adverse effect
Allosteric modulator
Pharmacology
3
Papers
17
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.
2021
Journal of the Neurological Sciences
Amy Bullock
Inder Kaul
Sigui li
Christopher Silber
James J. Doherty
Stephen Kanes
Show All
Source
Cite
Save
Citations (1)
A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults.
2021
Human Psychopharmacology-clinical and Experimental
Amy Bullock
H Gunduz-Bruce
Gary Zammit
Min Qin
Haihong Li
Abdul J. Sankoh
Christopher Silber
Stephen Kanes
Jeffrey Jonas
James J. Doherty
Show All
Source
Cite
Save
Citations (0)
SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
2019
Clinical Pharmacokinectics
Ethan Hoffmann
George G. Nomikos
Inder Kaul
Shane Raines
Jeff Wald
Amy Bullock
Abdul J. Sankoh
James Doherty
Stephen Kanes
Helen Colquhoun
Show All
Source
Cite
Save
Citations (16)
1